Contact Us

If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

You can contact us by phone, fax, or email, or by filling out the form below.

Are you a patient with a question?
Consumer Affairs
Phone: 1-888-508-6978
Fax: 610-290-9729
Email: cslb-consumeraffairs@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Are you a healthcare professional with a product-related question?
Medical Information
Phone: 1-800-504-5434
Fax: 610-878-4550
Email: medinfona@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Would you like to report an undesirable effect with use of a CSL Behring product?
If you experience any undesirable side effect(s) with a CSL Behring product, talk to your doctor, pharmacist, or nurse. If you would like to report the side effect(s) to CSL Behring, please contact us at:
CSL Behring US Pharmacovigilance
Phone: 1-866-915-6958
Email: Adverse.Events.Global@cslbehring.com
(Available 24 hrs/day)
You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Do you have a media-related question or comment?
Corporate Media Inquiries
Chris Florentz
Phone: 610-878-4316
Fax: 610-290-9316
Product-Related Media Inquiries
Anthony Farina
Phone: 610-878-4665
Fax: 610-290-9665
(Standard business hours are 8:30 am - 5:00 pm ET)
Do you have a question or comment about CSL Plasma or the plasma donation process?
CSL Plasma

Visit the CSL Plasma website to get more information on donating plasma or to send your questions and comments.

For all other questions, please contact...
CSL Behring Headquarters, North America
Phone: 610-878-4000
Fax: 610-878-4009
Address:

PO Box 61501
1020 First Avenue
King of Prussia, PA 19406-0901 USA

(Standard business hours are 8:30 am - 5:00 pm ET)

Comments/Inquiries Form

Type the verification text in the box below:

Verification Word
By submitting this form, you are consenting to receive an email response with relevant information from CSL Behring. You may also receive relevant information from CSL Behring in the future. You will have the ability to opt out from receiving CSL Behring emails or mailings at any time. View our Privacy Policy here.
CRP16-07-0005 8/2016
Important Safety Information
Expand

Important Safety Information

WARNING: Thrombosis (blood clots) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of blood clots, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor for signs of clotting events and hyperviscosity. Always drink sufficient fluids before infusing Hizentra.

See your doctor for a full explanation, and the full prescribing information for complete boxed warning.

Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, is a prescription medicine used to treat:

  • Primary immune deficiency (PI) in patients 2 years and older
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults

Treatment with Hizentra might not be possible if your doctor determines you have hyperprolinemia (too much proline in the blood), or are IgA-deficient with antibodies to IgA and a history of hypersensitivity. Tell your doctor if you have previously had a severe allergic reaction (including anaphylaxis) to the administration of human immune globulin. Tell your doctor right away or go to the emergency room if you have hives, trouble breathing, wheezing, dizziness, or fainting. These could be signs of a bad allergic reaction.

Inform your doctor of any medications you are taking, as well as any medical conditions you may have had, especially if you have a history of diseases related to the heart or blood vessels, or have been immobile for some time. Inform your physician if you are pregnant or nursing, or plan to become pregnant.

Infuse Hizentra under your skin only; do not inject into a blood vessel. Self-administer Hizentra only after having been taught to do so by your doctor or other healthcare professional, and having received dosing instructions for treating your condition.

Immediately report to your physician any of the following symptoms, which could be signs of serious adverse reactions to Hizentra:

  • Reduced urination, sudden weight gain, or swelling in your legs (possible signs of a kidney problem).
  • Pain and/or swelling or discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, or numbness/weakness on one side of the body (possible signs of a blood clot).
  • Bad headache with nausea; vomiting; stiff neck; fever; and sensitivity to light (possible signs of meningitis).
  • Brown or red urine; rapid heart rate; yellowing of the skin or eyes; chest pains or breathing trouble; fever over 100°F (possible symptoms of other conditions that require prompt treatment).

Hizentra is made from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

The most common side effects in the clinical trials for Hizentra include redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible. Tell your doctor about any side effect that bothers you or does not go away.

Before receiving any vaccine, tell immunizing physician if you have had recent therapy with Hizentra, as effectiveness of the vaccine could be compromised.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
Patient/Caregiver Contact Us
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® and MyHizentra® are registered trademarks of CSL Behring AG.
Biotherapies for Life® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM, IgIQSM, and Premier StartSM are service marks of CSL Behring LLC.
Voice2Voice® is a registered trademark of CSL Behring GmbH.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ-0316-MAR18